https://allsci.com/news/clinical-trials/nonsegmental-vitiligo-litfulo-phase-iii-data-back/ AllScien 2026-10-02T17:05:04.622425Z Litfulo Phase III data support Pfizer’s push into systemic vitiligo treatment https://allsci.com/news/clinical-trials/atopic-dermatitis-pfizers-trispecific-tilrekimig/ AllScien 2026-10-02T17:01:49.012568Z Pfizer’s tilrekimig delivers Phase II skin clearance ahead of dupilumab head-to-head https://allsci.com/news/biotech/ubamatamab-lgsoc-shows-early-promise-in-small/ AllScien 2026-10-02T16:57:16.825538Z Regeneron’s ubamatamab posts 73% response rate in small LGSOC cohort https://allsci.com/news/clinical-trials/trevogrumab-trial-courage-data-back-as-muscle/ AllScien 2026-10-02T16:27:17.650948Z Regeneron’s trevogrumab cuts lean-mass loss in Phase II obesity trial